Lancet Neurology

Article	Citations
Multidisciplinary care for amyotrophic lateral sclerosis	958
Correction to Lancet Neurol 2021; 20: 448–59	863
Correction to Lancet Neurol 2024; 23: 168–77	822
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	707
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	635
Anti-CD19 CAR T cells for refractory myasthenia gravis	506
Management of atherosclerotic extracranial carotid artery stenosis	501
A biological classification of Huntington's disease: the Integrated Staging System	469
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	459
RAB32 mutation in Parkinson's disease	439
Correction to Lancet Neurol 2025; 24: 850–65	409
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	394
The relevance of social and commercial determinants for neurological health	361
Traumatic brain injury research: homogenising heterogeneity	347
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	337
Increasing diversity in dementia research	335
The predictive value and clinical use of the neurological pupillary index – Authors' reply	324
Dementia diagnosis in the anti-amyloid era	289
Lessons and future directions for GBA1-targeting therapies	279
Correction to Lancet Neurol 2022; 21: 42–52	259
The East Asian Parkinson Disease Genomics Consortium	245
New therapies for Pompe disease: are we closer to a cure?	232
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	230
Implications of the KIWE trial for low-income and lower-middle-income countries	230
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	229

Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	227
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	212
Global burden of stroke: dynamic estimates to inform action	196
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	191
Surrogate endpoints for progressive multifocal leukoencephalopathy	181
The prescription of valproate: risk of harm	176
Diana Cejas	175
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	172
Considering the neurological health needs of LGBTQIA people	171
Safe laboratory management of prions and proteopathic seeds	168
Movement disorders research in 2021: cracking the paradigm	167
Elia M Pestana Knight	167
Beyond the modular brain	158
Aspiring to restore arm and hand function after stroke	155
Albert Kwaku Akpalu	153
A sensitive portrayal of a controversial condition	150
A chilly tale of dementia	146
A nasal CGRP receptor antagonist for acute migraine therapy	145
A study in healing the wounds of trauma	143
Correction to Lancet Neurol 2023; 22: 812–25	141
Trials in intracerebral haemorrhage: a path to success?	141
Gene therapy for X-linked myotubular myopathy: the challenges	140
Parkinson's disease is a recognisable and useful diagnostic entity	135
Delving into the human mind	133
Correction to Lancet Neurol 2022; 21: 284–94	130
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment	128
Epilepsy syndromes: an essential piece of the puzzle	125
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	120
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	115
Development of treatments for Down syndrome	115
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	114
From stroke awareness to stroke action awareness	113
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	112
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	111
Amyotrophic lateral sclerosis from genotoxins alone?	110
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	109
Functional or hysterical?	109
Cognitive function in people with functional seizures	109
Revisiting candesartan: new evidence for an old option in migraine prevention	108
Changing multiple-sclerosis-induced thoughts and behaviours	106
Supporting young carers across neurological disorders	105
Learning to be an adult with a disability	104
α-synuclein seed amplification and its uses in Parkinson's disease	102
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	100
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	98
A proposal for equity neuroscience	97
Rethinking AI trials in brain health	97
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	95
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	94
Multiple sclerosis in 2022: old players, new insights	93

A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	92
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial	91
New results for risdiplam in spinal muscular atrophy	89
Major advances in Parkinson's disease over the past two decades and future research directions	89
Expansion of stenting indications in the USA	88
Responsible innovation in neurology	87
Correction to Lancet Neurol 2024; 23: 110–22	86
Correction to Lancet Neurol 2022; 21: 620–31	86
Brain health in the Philippines	84
Jessica Ailani	82
Encephalitis awareness: our ambitious global endeavour	82
The International Brain Initiative: enabling collaborative science	81
Better buildings for elderly people to thrive	81
Detection of ionising radiation by the CNS: a case report	80
Neurological infections in 2023: surveillance and prevention	79
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	79
Spontaneous intracranial hypotension: searching for the CSF leak	78
Siddharth Srivastava	78
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	78
Detection of awareness after brain injury: time for change	77
Improving thrombolysis efficiency for acute ischaemic stroke	77
Pragmatic solutions for the global burden of stroke	76
ELEVATEd hope for patients after migraine treatment failure	76
A call for optimal oral care in patients with ALS	76
Monitoring brainwaves while gallery visitors view artworks	73
Highlights in traumatic brain injury research in 2024	73
Andrea Schneider	73
Correction to Lancet Neurol 2024; 23: 961–62	73
Neuroprotection in acute ischaemic stroke: reasons for optimism?	72
Expanding the spectrum of type 1 IFN neuroinflammation	68
Neurorehabilitation as a cornerstone of recovery	67
Correction to Lancet Neurol 2024; 23: 344–81	67
Thrombolysis before endovascular treatment of tandem lesions	67
Consciousness contextualised	66
Epilepsy research in 2022: clinical advances	65
Targeting auto-antibodies for CIDP: hope and questions	65
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	65
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	62
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	62
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	62
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	61
Living with dementia: seeing the world and adapting to it	60
The global challenge of hypertension	60
Eugenia Martínez	59
Blocking inhibitors of axon growth after spinal cord injury	59
Your After-Visit Summary—May 29, 2042	58
Sleeping matters	53
Brains are neither pink nor blue but fifty shades of grey matter	53
Bastiaan Bloem: power against Parkinson's disease	52
Headache research in 2023: advancing therapy and technology	51
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	51
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	51
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	50
The AfrAbia+plus Parkinson's Disease Genomic Consortium	50
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	50
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	49
Diagnosis and treatment of orthostatic hypotension	49
Correction to Lancet Neurol 2024; 23: 465–76	48
Therapies for myasthenia gravis: FcRn inhibition and beyond	48
The torment of needing to know for sure	48
Angela Dos Santos	47
Changing the landscape of neurological education	47
NfL is ready for translation into paediatrics	46
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	46
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	46
Charles Bell's Renaissance inspiration	46
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	45
Over a decade of MR-guided focused ultrasound	45
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	45
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	44
The bases of remembrance	43
Early atrial fibrillation rhythm control after stroke	43
Correction to Lancet Neurol 2021; 20: 1012–16	43
Geoffrey Manley: TBI guy	43
No area of stroke research should be left behind	43
The cultural history of dementia	42
Carlayne Jackson: leading the American Academy of Neurology	42
Advances in amyotrophic lateral sclerosis research in 2022	42
Major advances in sleep neurology: 2002–22	42
Neurosurgical lesioning for Tourette syndrome – Authors' reply	42

Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	41
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	41
Further support for rituximab in relapsing multiple sclerosis	40
A brain design for life	40
Digital mobility measures to predict Parkinson's disease	39
Charles Sherrington's apparatus	39
Laquinimod, Huntington's disease, and disease modification	38
For a dementia diagnosis, clinical acumen must precede biomarkers	38
Sleep research in 2023: beyond the bare necessities	38
Essential medicines for neurological disorders: updates, rejections, and the road ahead	37
Thank you to The Lancet Neurology's peer reviewers in 2023	37
The complex pathway between amyloid β and cognition: implications for therapy	37
Biomedical research must change as the climate does	37
Frailty and outcome after traumatic brain injury	36
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	36
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	36
A decisive year for the neurological community	36
Improving epilepsy diagnosis across the lifespan: approaches and innovations	35
Globally advancing neurological education in headache	35
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	35
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	35
Nanna Brix Finnerup: integrity and openness to alternatives	34
Acute-onset axonal neuropathy following infection in children with biallelic RCC1 variants: a case series	34
Maria Trojano: advocate for real-world multiple sclerosis studies	32
Video games for people with neurological disorders	32
The prescription of valproate: risk of harm	31
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	30
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	30
Correction to Lancet Neurol 2024; 23: 344–81	30
Correction to Lancet Neurol 2025; 24: 880–92	29
Neuroscience research in 2024: advances in blood biomarkers and brain omics	29
Nitrous oxide and its neurological harms	29
Abandon the NAC in α-synuclein	29
Blue as an orange	28
Sleep matters in anti-LGI1 encephalitis	28
RAB32 mutation in Parkinson's disease	28
Global burden of meningitis and implications for strategy	27
Helping to bring the crisis home	27
Correction to Lancet Neurol 2023; 22: 209–17	27
Revisiting levodopa for advanced Parkinson's disease	26
Neuroscience in the 21st century: circuits, computation, and behaviour	26
Friston's theory of everything	26
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	26
Teshamae Monteith	26
Correction to Lancet Neurol 2018; 17: 954–76	25
Time to get serious about the Global Action Plan on dementia	25
Correction to Lancet Neurol 2021; 20: 615–26	25
Advances in diagnosis, classification, and management of pain in Parkinson's disease	25
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	24
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	24
Addressing neurological burden in the Americas	24
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	24
A neurotransmitter with a fascinating story	23
Amyotrophic lateral sclerosis: a lesson in translation	23
Carotid revascularisation for carotid stenosis	23
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	22
Transforming amyotrophic lateral sclerosis into a liveable disease	22
CGRP blockade and cluster headache: another step forward	22
Neurology cannot be embedded in non-communicable disease agendas	22
A disease-specific therapy in facioscapulohumeral muscular dystrophy	22
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	22
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	21
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	21
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	21
The hidden unity of the mind	21
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	21
Carpal tunnel syndrome: updated evidence and new questions	21
Time to end the stigma of epilepsy	21
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	21
Chronic effects of inflammation on tauopathies	21
Innovation in the prevention of neurological diseases	21
Cerebral amyloid angiopathy criteria: the next generation	21
Fetal exposure to antiseizure medications: reassurance and concerns	20
With thanks to our peer reviewers in 2022	20
Lightning progress in child neurology in the past 20 years	20
CGRP-targeted drugs for migraine: still many uncertainties	20
Vittorio Marchi's staining	20
Treatment of acute subdural haematoma – Authors' reply	20
Treatment of asymptomatic carotid stenosis in SPACE-2	20
The neuropsychiatry of Parkinson's disease: advances and challenges	18
Dancing with paper	18
Differential diagnosis of suspected multiple sclerosis: global health considerations	18
William Harvey, neurologist?	18
Mar Tintoré, Mar Mediterráneo	17
Pragmatic solutions for the global burden of stroke	17
Targeting C9orf72 in people with ALS	17
Elucidating a new path of CSF transport in the CNS	17
Changing views of disability	17
Everything is connected: sparks will fly in coproduction spaces	17
Dealing with the reproducibility crisis in neuroscience from the grassroots	17
Safety and effectiveness of the Walk ‘n Watch structured, progressive exercise protocol delivered by physical therapists for inpatient stroke rehabilitation in Canada: a phase 3, multisite, pragmatic,	17
Correction to Lancet Neurol 2025; 24: 486–87	17
Antibiotic neuromuscular junction myasthenic mimetics	16
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study	16
Effects of spaceflight on the brain	16